++
The semi-implantable Vibrant Soundbridge® (Med-El, Innsbruck, Austria), the totally implantable Envoy Esteem™ (Envoy Medical, Minneapolis, MN), and the totally implantable Carina™ (Otologics LLC, Boulder, CO) devices featured in this section are examples of innovative IMEHD technologies. The Vibrant Soundbridge® is currently the only FDA-approved device within the United States and is also available in Europe. The Envoy Esteem, a totally implantable device, has recently been recommended for approval by an advisory panel to the FDA in the United States. It is currently available in many European countries as well as Brazil, Iran, and India. The Carina™ is currently undergoing Phase II FDA trials in the United States.
++
The Vibrant Soundbridge is a semi-implantable device that uses an electromagnetic effector to drive the ossicular chain. The external component is the audio processor, and the internal component is the surgically implanted vibrating ossicular prosthesis. The audio processor houses the microphone, the speech processor, and the battery. The vibrating ossicular prosthesis (Figure 67–1) contains the radiofrequency link, the demodulator, and the ossicular stimulator–the floating mass transducer–which is attached to the incus lenticular process with a titanium clip. The floating mass transducer is an electromagnetic effector with a magnet housed within an induction coil.
++
+++
Implantation & Candidate Criteria
++
The surgical procedure consists of a mastoidectomy with a facial recess approach to place the floating mass transducer onto the lenticular process. After a 2-month period of healing, the device is activated. The speech processor delivers electronically controlled currents to drive the floating mass transducer into vibratory motion. Candidates for implantation are adults (⩾18 years) with a moderate-to-severe sensorineural hearing loss and speech discrimination scores >50%. Recent studies have also shown that placement of the floating mass transducer either directly on the round window membrane or on the stapes in the absence of the incus have promising results, suggesting that this is an alternative form of hearing amplification for patients with otosclerosis and aural atresia.
++
For the Vibrant Soundbridge Phase III FDA study, statistically significant improvements in average functional gain on the order of 10–15 dB across the frequency spectrum were reported. Mass loading of the incus did not adversely affect hearing in a clinically significant manner. Subjects reported improved satisfaction and performance; they preferred the Vibrant Soundbridge to a heterogeneous group of conventional hearing aids. Occlusion and feedback were virtually eliminated. Of note, aided speech recognition was comparable between the Vibrant Soundbridge and conventional hearing aids.
++
The trial also demonstrated acceptable safety. Most patients did not have a significant change in residual hearing (ie, change in pure-tone average <10 dB). However, a small percentage of patients (4% or 2 of 53 patients) experienced a 12–18 dB decrease in residual hearing. Other adverse effects have been reported during the U.S. trial. There were six device failures; these devices were successfully reimplanted after the manufacturer revised the product. One subject had a disconnection of the floating mass transducer; the device was successfully reimplanted.
++
The Envoy Esteem™ is a totally implantable hearing device that uses piezoelectric transducers. A major design challenge of totally implantable hearing devices is the management of mechanical and acoustic feedback. By necessity, receptor (sensor) and effector (driver) limbs of the system are in close proximity. At high output levels by the effector limb, feedback may occur because the sensor detects the output signal. This results in feedback oscillation. The Envoy system addresses this difficult problem by segregating the receptor and effector limbs through controlled ossicular discontinuity. The device has now received FDA approval and is available in the United States.
+++
Implantation & Candidate Criteria
++
The surgical procedure is a mastoidectomy with a facial recess approach to vaporize the distal 2–3 mm of the incus lenticular process with a laser (Figure 67–2). Bone cement is used to stabilize the sensor and driver to the mastoid and to affix the device tips to the incus body and stapes capitulum. When incoming sounds vibrate the native drum, the incus head is set in motion. The sensor tip, which is firmly attached to the incus head, deflects the piezoelectric transducer. Electrical signals are generated and transmitted to the speech processor. Outflow electrical signals from the processor guide the movements of the driver tip, which is transmitted to the stapes. Candidates for the Envoy device implantation are adults (⩾18 years) with a mild-to-severe sensorineural hearing loss and speech discrimination scores ⩾60%.
++
+++
Phase I Testing and Safety Data
++
For the Envoy Esteem™ Phase I FDA study in seven patients, five of seven perceived benefit over their best-fit hearing aid at the 2-mo activation period. Two of the five patients who ultimately experienced benefit required revision surgery after initial implantation because immediate benefit was insufficient. In the original cohort of seven patients, three were explanted owing to infection or patient request. Functional gain with the Esteem™ was similar to hearing aids. Cochlear reserve in study patients appeared to be preserved following Esteem™ implantation, whereas air conduction thresholds for frequencies greater than 1 kHz were increased by 10–20 dB at 12 months after implantation. Device modifications were implemented prior to Phase III trial.
++
Initially developed as a semi-implanatable device, the Otologics Carina™ device is now a fully implantable device that incorporates a microphone, speech processor, battery, and transducer into a prosthesis. The microphone, located under the postauricular skin, amplifies sound and converts acoustic signals to electrical signals that are transmitted to the transducer. Thereafter, the ossicular stimulator vibrates the ossicles. The subcutaneous battery is charged daily with a radiofrequency coil that is placed over the implant site. The implant is programmable and the volume can be adjusted with a remote control that sits over the implant.
+++
Implantation & Candidate Criteria
++
The surgical procedure is a modified atticotomy that exposes the body of the incus and the head of the malleus. A mounting plate with a retaining ring is affixed to the mastoid cortex with self-tapping screws that allows the electronics capsule to be secured. A laser is used to create a hole in the midbody of the incus. The transducer is mounted to the retaining ring with its probe tip is advanced into the hole of the incus. Electrical stimulation of the transducer translates into mechanical stimulation of the ossicular chain. After a 6- to 8-week healing period, the device can be activated. Candidates for the Otologics device are similar to that for the Envoy Esteem.
+++
Phase I Testing and Safety Data
++
A study of 20 implanted patients demonstrated that although their conventional hearing aids had slightly better pure-tone averages and monaural word recognition scores, patients preferred hearing with the Carina™, noting improved quality of sound, improved ability to hear soft sounds, comfort, and ability to use the device in noisy conditions. Complications included implant extrusion in three of the patients, requiring explantation in two, increased charging times in seven patients, resulting in two no longer using their implants, and loss of external communication with the implant, making it unable to be charged. It was also noted that at 6 months after implantation, there was decreased usage of the implant secondary to decreased speech perception. It is believed that this is a result of the migration of the microphone and processors. Since this trial, modifications to the device to address these issues have been made as it enters Phase II testing.
+++
Bone-Anchored Hearing Aids
++
While it is not an implantable middle ear device, the BAHA (Cochlear Corporation, Sydney, Australia) is an FDA-approved implant for patients with conductive hearing loss, mixed hearing loss, or unilateral sensorineural hearing loss who cannot tolerate or have limited benefits from conventional air conduction hearing aids. Traditional bone conduction hearing aids require the use of a head band to secure the transducer to the head. With the BAHA, not only is the band no longer required but also the coupling between the transducer and the microphone is significantly better, as much as by 10–15 dB. Disadvantages of the BAHA include a higher cost and requirement of a surgical procedure. However, the improvement in hearing and communication has made the BAHA an appealing option for certain groups of patients with hearing loss.
+++
Implantation & Candidate Criteria
++
The surgical procedure consists of creating thin skin flap, about the thickness of a full-thickness skin graft. A titanium abutment is installed into the temporal bone and the thin skin flap with a center hole is draped over the implant. The wound is then allowed to heal for 3–4 months for osseointegration to take place.
++
The BAHA was originally indicated for patients with a conductive or mixed hearing loss with a conductive component >30 dB. Patients with chronically draining ears despite vigorous treatment, bilateral congenital aural atresia, and conductive loss in the only hearing ear have been the primary beneficiaries. More recently, patients with single-sided deafness have been shown to benefit from the BAHA.
Backous DD, Duke W. Implantable middle ear hearing devices: Current state of technology and market challenges. Curr Opin Otolaryngol Head Neck Surg. 2006;14:314.
Barbara, M, Manni V, Monini S. Totally implantable middle ear device for rehabilitation of sensorineural hearing loss: Preliminary experience with the Esteem, Envoy. Acta Otolaryngol. 2009;129:429.
Chen DA, Backous DD, Arriaga MA et al. Phase 1 clinical trial results of the envoy system: A totally implantable middle ear device for sensorineural hearing loss. Otolaryngol Head Neck Surg. 2004;131(6):904.
Falcone MT, Kaylie DM, Labadie RF et al. Bone-anchored hearing aid abutment skin overgrowth reduction with
clobetasol.
Otolaryngol Head Neck Surg. 2008;139(6):829.
Fisch U, Cremers CW, Lenarz T et al. Clinical experience with the Vibrant Soundbridge implant device. Otol Neurotol. 2001;22(6):962.
Fraysse B, Laveille JP, Schmerber S et al. A multicenter study of the Vibrant Soundbridge middle ear implant: Early clinical results and experience. Otol Neurotol. 2001;22(6):952.
Frenzel H, Hanke F, Beltrame M. Application of the Vibrant Soundbridge to unilateral osseous atresia cases. Laryngoscope. 2009;119(1):67.
Haynes DS, Young JA, Wanna GB et al. Middle ear implantable hearing devices: An overview. Trends Amplific. 2009;13(3):206.
House JW, Kutz JW. Bone-anchored hearing aids: Incidence and management of postoperative complications. Otol Neurotol. 2007;28(2):213.
Jenkins HA, Atkins JA, Horlbeck D et al. Otologics fully implantable hearing system: Phase I trial 1-year results. Otol Neurotol. 2008;29(4):534.
Ko WH, Zhu WL, Kane M, Maniglia AJ. Engineering principles applied to implantable otologic devices. Otolaryngol Clin North Am. 2001;34(2):299.
Luetje CM, Brackman D, Balkany TJ et al. Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device: A prospective controlled multicenter study. Otolaryngol Head Neck Surg. 2002;126(2):97.
Snik AF, Bosman AJ, Mylanus EA et al. Candidacy for the bone-anchored hearing aid. Audiol Neurootol. 2004;9(4):190.
Snik AF, Mylanus EAM, Proops DW et al. Consensus statements on the BAHA system: Where do we stand at present? Annals of Oto, Rhino, Laryngol. 2005:114(12)Suppl 195:1.
++
We would like to acknowledge Kenneth C.Y. Yu, MD for his contribution to this chapter in the previous editions of CDT.